The 20 Best Chromophobe Renal Cell Carcinoma Doctors Near Me in Jersey City, NJ

Paul Russo is a Urologist practicing medicine in New York, New York. Dr. Russo is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Wilms Tumor, Nephrectomy, and Reconstructive Urology Surgery. Dr. Russo is currently accepting new patients.

Martin Voss is an Oncologist practicing medicine in New York, New York. Dr. Voss is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Nephrectomy. Dr. Voss is currently accepting new patients.

Jonathan Coleman is a Urologist practicing medicine in New York, New York. Dr. Coleman is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Prostatectomy. Dr. Coleman is currently accepting new patients.

Abraham Hakimi is a Urologist practicing medicine in New York, New York. Dr. Hakimi is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery. Dr. Hakimi is currently accepting new patients.

Robert Motzer is an Oncologist practicing medicine in New York, New York. Dr. Motzer is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Teratoma of the Mediastinum, Nephrectomy, and Orchiectomy. Dr. Motzer is currently accepting new patients.

John Sfakianos is a Urologist practicing medicine in Astoria, New York. Dr. Sfakianos is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Sfakianos is currently accepting new patients.

Ketan Badani is a Urologist practicing medicine in New York, New York. Dr. Badani is rated as an Elite provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

Thomas Bradley, MD, FACP, is Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. As System Head for Genitourinary Cancers for the Northwell Health Cancer Institute, Dr. Bradley has special expertise in the management of prostate, kidney, bladder, and testicular cancers. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Bradley maintains an active practice where he focusses on providing compassionate, personalized, evidence-based multi-disciplinary care. Dr. Bradley has a keen interest in the education of future physicians as evidenced by his directorship of the Fellowship program in Hematology and Medical Oncology for many years. His research work as principal investigator for numerous drug trials and multiple collaborations has resulted in dozens of publications and abstracts. Dr. Bradley earned his medical degree from the University of Monterrey School of Medicine. He trained in internal medicine as well as hematology and medical oncology at the State University of New York at Downstate Medical Center. Dr. Bradley is an active member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research and the American College of Physicians. Dr. Bradley is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Upper Tract Urothelial Carcinoma (UTUC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, and Bone Marrow Aspiration. Dr. Bradley is board certified in American Board Of Internal Medicine, American Board Of Internal Medicine/Hematology, and American Board Of Internal Medicine/Medical Oncology.

Daniel Cho is an Oncologist practicing medicine in New York, New York. Dr. Cho is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Familial Wilms Tumor 2, and Renal Cell Carcinoma (RCC).

Arjun Balar is an Oncologist practicing medicine in New York, New York. Dr. Balar is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Prostate Cancer, Muscle Invasive Bladder Cancer, and Thrombectomy.

William Huang is a Urologist practicing medicine in New York, New York. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

James Wysock is a Urologist practicing medicine in New York, New York. Dr. Wysock is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Urachal Cyst, Renal Cell Carcinoma (RCC), Nephrectomy, and Prostatectomy.

Michael Palese is a Urologist practicing medicine in New York, New York. Dr. Palese is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Enlarged Prostate (BPH), Clear Cell Sarcoma, Nephrectomy, and Reconstructive Urology Surgery. Dr. Palese is currently accepting new patients.

David Nanus is an Oncologist practicing medicine in Brooklyn, New York. He has been practicing medicine for over 44 years. Dr. Nanus is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Orchiectomy, and Tissue Biopsy. Dr. Nanus is currently accepting new patients.

David Silver is a Urologist practicing medicine in Brooklyn, New York. Dr. Silver is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Vasectomy, and Reconstructive Urology Surgery.

Dr Steven Berman has been in practice for 25 years specializing in General Urology. Dr. Berman is rated as an Experienced provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Enlarged Prostate (BPH), Prostate Cancer, Familial Prostate Cancer, and Urinary Tract Infection in Children.

Jasmine Francis is an Oncologist practicing medicine in New York, New York. Dr. Francis is rated as an Advanced provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Retinoblastoma, Melanoma of the Eye, Metastatic Uveal Melanoma, Vitrectomy, and Liver Embolization. Dr. Francis is currently accepting new patients.

Lee Richstone, MD is the Chairman of Urology and Director of Urology Services for the Western Region. He is also Director of Laparoscopic and Robotic Surgery at Lenox Hill Hospital and System Vice Chairman for Education for Northwell Health Urology. Dr. Richstone is Professor of Urology at The Hofstra-Northwell School of Medicine. Dr. Richstone completed medical school at the Cornell University Medical College in New York City. There he won early acceptance into Alpha Omega Alpha (AOA), the prestigious national medical honor society. He pursued his urologic training and chief residency at New York Presbyterian (Weill-Cornell) and Memorial Sloan Kettering hospitals. Dr. Richstone completed his fellowship training in urologic laparoscopic and robotic surgery and joined the North Shore Long Island Jewish Health System in 2007 as Director of Laparoscopic and Robotic Surgery. He then served as Chief of Urology for the North Shore University Hospital, then Chief of Urology at the Long Island Jewish Medical Center, before assuming the role of Chairman of Urology at Lenox Hill Hospital in Manhattan. Dr. Richstone is an internationally recognized urologic surgeon who has helped pioneer laparoscopic and robotic surgery for cancer of the prostate, kidney and bladder, as well as for various forms of urinary obstructions. He has over 90 peer-reviewed publications in leading national and international journals including The Journal of Urology, Urology, The British Journal of Urology, The Journal of Endourology, Cancer, and Cell.Dr. Richstone is a robotic surgery specialist having performed well over 1000 operations. This includes surgeries for prostate, kidney and bladder cancer and complex neobladder reconstructions completely robotically. His focus is on preserving urinary continence and sexual function. Dr. Richstone has also pioneered Laparoendoscopic Single Site Surgery (LESS), where entire laparoscopic operations are performed only through the belly button. Dr. Richstone is one of only a few surgeons in the United States to have performed single site partial nephrectomy and prostatectomy.Dr. Richstone is a member of the Society of Urologic Oncology (SUO), the America Urological Association (AUA), and the Endourological Society (EUS). Dr. Richstone is the recipient of numerous honors and awards, including acceptance into Alpha Omega Alpha (AOA), the E. Darracott Vaughan Prize for Excellence in Urology (2000), The Ferdinand C. Valentine Urology Essay Prize (First Place, 2005), The American Urological Association-Ambrose Reed Socioeconomic Essay Contest (First Place, 2005), and the Weill-Cornell Distinguished House Officer Award (2005). Dr. Richstone was awarded the Stryker and Nagamatsu Fellowship (2007), and won first prize at the Endourology Society Fellowship Paper Award the same year. Dr. Richstone won first prize at the AUA Research Foundation for Outstanding Research awarded at the 2010 AUA National Meeting in San Francisco. Dr. Richstone is rated as an Advanced provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Richstone is board certified in American Board Of Urology.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy. Dr. Mckiernan is board certified in Urology. Dr. Mckiernan is currently accepting new patients.

Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute.Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer. Dr. Stein is rated as a Distinguished provider by MediFind in the treatment of Chromophobe Renal Cell Carcinoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and Familial Prostate Cancer. Dr. Stein is board certified in Medical Oncology. Dr. Stein is currently accepting new patients.